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Abstract
Objective:  To  describe  the  impact  of  varicella  vaccination  on  varicella-related  hospitalization
rates in  countries  that  implemented  universal  vaccination  against  the  disease.
Data source:  We  identiﬁed  countries  that  implemented  universal  vaccination  against  varicella
at the  http://apps.who.int/immunization  monitoring/globalsummary/schedules  site  of  the
World Health  Organization  and  selected  articles  in  Pubmed  describing  the  changes  (pre/post-
vaccination)  in  the  varicella-related  hospitalization  rates  in  these  countries,  using  the  Keywords
‘‘varicella’’,  ‘‘vaccination/vaccine’’  and  ‘‘children’’  (or)  ‘‘hospitalization’’.  Publications  in
English published  between  January  1995  and  May  2015  were  included.
Data synthesis:  24  countries  with  universal  vaccination  against  varicella  and  28  articles  describ-
ing the  impact  of  the  vaccine  on  varicella-associated  hospitalizations  rates  in  seven  countries
were identiﬁed.  The  US  had  81.4%--99.2%  reduction  in  hospitalization  rates  in  children  younger
than four  years,  6--14  years  after  the  onset  of  universal  vaccination  (1995),  with  vaccination
coverage  of  90%;  Uruguay:  94%  decrease  (children  aged  1--4  years)  in  six  years,  vaccination
coverage of  90%;  Canada:  93%  decrease  (age  1--4  years)  in  10  years,  coverage  of  93%;  Germany:
62.4% decrease  (age  1--4  years)  in  8  years,  coverage  of  78.2%;  Australia:  76.8%  decrease  (age
1--4 years)  in  5  years,  coverage  of  90%;  Spain:  83.5%  decrease  (age  <5  years)  in  four  years,
coverage  of  77.2%  and  Italy  69.7%--73.8%  decrease  (general  population),  coverage  of  60%--95%.
Conclusions:  The  publications  showed  variations  in  the  percentage  of  decrease  in  varicella-
related hospitalization  rates  after  universal  vaccination  in  the  assessed  countries;  the  results
probably depend  on  the  time  since  the  implementation  of  universal  vaccination,  differences
in the  studied  age  group,  hospital  admission  criteria,  vaccination  coverage  and  strategy,  which
does not  allow  direct  comparison  between  data.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
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de  dados  mundiais
Resumo
Objetivo:  Descrever  o  impacto  da  vacina  varicela  nas  taxas  de  internac¸ões  hospitalares  associ-
adas à  varicela  nos  países  que  adotaram  a  vacinac¸ão  universal  contra  a  doenc¸a.
Fontes  de  dados:  Identiﬁcaram-se  países  que  adotaram  a  vacinac¸ão  universal  contra
varicela pelo  site  http://apps.who.int/immunization  monitoring/globalsummary/schedules  da
Organizac¸ão Mundial  de  Saúde  e  selecionaram-se  os  artigos  no  Pubmed  que  descrevem  a
variac¸ão (pré/pós-vacinal)  nas  taxas  de  internac¸ões  relacionadas  à  varicela  desses  países,
com auxílio  das  palavras  chaves:  ‘‘varicella’’,  ‘‘vaccination/vaccine’’  e  ‘‘children’’  (ou)
‘‘hospitalization’’.  Incluíram-se  publicac¸ões  em  inglês  entre  janeiro  de  1995  e  maio  de  2015.
Síntese dos  dados:  Foram  identiﬁcados  24  países  com  vacinac¸ão  universal  contra  a  varicela  e
28 artigos  que  descrevem  o  impacto  da  vacina  nas  internac¸ões  associadas  à  varicela  em  sete
países. Os  EUA  tiveram  81,4%-99,2%  de  reduc¸ão  na  taxa  de  internac¸ão  em  crianc¸as  menores
de quatro  anos,  após  6-14  anos  do  início  da  vacinac¸ão  universal  (1995),  com  cobertura  vacinal
de 90%;  Uruguai:  94%  de  queda  (crianc¸as  de  1-4  anos)  em  6  anos,  cobertura  vacinal  de  90%;
Canadá: 93%  de  reduc¸ão  (1-4  anos)  em  10  anos,  cobertura  de  93%;  Alemanha:  62,4%  de  reduc¸ão
(1-4 anos)  em  8  anos,  cobertura  de  78,2%;  Austrália:  queda  de  76,8%  (1-4  anos)  em  5  anos,
cobertura de  90%;  Espanha:  83,5%  de  queda  (<  5  anos)  em  4  anos,  cobertura  de  77,2%;  e  Itália:
queda entre  69,7%-73,8%  (populac¸ão  geral),  cobertura  de  60%-95%.
Conclusões:  As  publicac¸ões  revelaram  variac¸ão  no  percentual  de  queda  na  hospitalizac¸ão  por
varicela após  a  vacinac¸ão  universal  nos  países  pesquisados;  os  resultados  provavelmente  depen-
dem do  tempo  decorrido  após  introduc¸ão  da  vacinac¸ão  universal,  diferenc¸as  na  faixa  etária
estudada, critérios  de  internac¸ão,  cobertura  vacinal  e  estratégia  de  vacina,  não  permitindo
comparac¸ão direta  entre  os  dados.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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aricella  is  caused  by  a  DNA  virus  of  the  Herpesviridae
amily.  It  is  highly  contagious,  with  an  annual  incidence
f  26--61  cases  per  1000  unvaccinated  individuals;  it  usu-
lly  has  a  benign  course,  but  can  evolve  with  complications
rom  the  virus  itself  or  from  secondary  bacterial  infections
n  both  immunodeﬁcient  patients  and  immunocompetent
ndividuals.1--4
Complications  from  varicella  virus  itself  are  pneumo-
ia,  acute  obstructive  respiratory  disease,  cerebellitis,
ncephalitis,  meningitis,  and  other  rarer  conditions  such
s  neutropenia,  thrombocytopenia,  Henoch--Schonlein,  syn-
vitis,  and  Reye’s  syndrome.5,6 The  complications  from
econdary  bacterial  infection  include  impetigo,  abscesses,
ellulitis,  necrotizing  fasciitis,  pneumonia,  toxic  shock  syn-
rome,  and  sepsis.7,8 Mortality  by  varicella  is  considered  low
6.7/100,000  infected),  but  the  disease  may  have  temporary
r  permanent  sequelae.9
The  varicella  vaccine  (VV)  with  live  attenuated  virus  (Oka
train)  was  developed  in  Japan  in  1974  and  its  commercial-
zation  started  in  1987.  In  1995,  the  United  States  (USA)
ecame  the  ﬁrst  country  to  include  it  in  the  national  immu-
ization  schedule.10 The  local  epidemiological  scenario  was
haracterized  by  an  incidence  of  four  million  cases,  11,000
ospitalizations,  and  100  deaths  yearly  due  to  varicella.5 In
006,  the  country  introduced  the  second  dose  of  vaccine  for
hildren  between  4  and  6  years,  in  order  to  reduce  commu-
ity  outbreaks.  Over  the  past  20  years,  other  countries  have
u
v
amplemented  universal  vaccination  against  this  disease  in
ne  or  two  doses,  according  to  the  criteria  of  each  country
r  region,  and  several  studies  analyzing  the  impact  of  this
easure  have  been  published.
In  Brazil,  varicella  is  not  a  compulsory  notiﬁcation  dis-
ase,  and  its  epidemiological  data  are  restricted  to  schools
nd  kindergardens  outbreak  reports,  and  DATASUS  (Ministry
f  Health)  information  generated  by  Hospital  Admissions
uthorizations  (Autorizac¸ões  de  Internac¸ão  Hospitalar  [AIH])
rom  the  National  Uniﬁed  Healthcare  System  (Sistema  Único
e  Saúde  [SUS]).11 According  to  DATASUS,  the  number  of
ospitalizations  for  varicella  in  Brazil  has  varied  between
200  and  7800  cases  yearly,  but  this  number  accounts
nly  for  the  hospitalizations  in  the  public  healthcare
ystem.
Following  the  global  trend  of  universal  implementa-
ion  of  VV,  the  Brazilian  Ministry  of  Health  announced,
n  September  2013,  the  inclusion  of  this  vaccine  in  the
ational  Immunization  Program  for  children  born  from  June
012  onwards.  The  one  dose  schedule  associated  with  the
easles,  mumps,  and  rubella  (MMR)  vaccine  at  15  months,
ithout  a  booster  dose;  varicella-related  hospitalizations
re  expected  to  decrease  by  80%.12 Two  years  after  the
mplementation  of  this  vaccine,  the  impact  of  this  mea-
ure  on  varicella-related  hospitalizations  in  Brazil  is  still
ndetermined.
This  study  aimed  to  describe  the  impact  of  VV  in
aricella-related  hospitalization  rates  in  countries  that  have
dopted  universal  vaccination  against  the  disease,  in  order
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Table  1  Countries  that  have  adopted  the  varicella  vaccine,
number  of  doses,  and  vaccination  schedule  adopted.
Country  Dose  Vaccination  schedule
Eastern  Mediterranean
Oman  1  12  months
Qatar  2  12  months  and  4--6  years
Saudi Arabia  2  12  months  and  6  years
United  Arab  Emirates  1  12  months
Europe
Germany  2  11--14  months  and  15--23
months
Greece  2  12--15  months  and  4--6
years
Israela 2  12  months  and  6  years
Italy 2  13--15  months  and  5--6
years
Latvia 1  12--15  months
Spain  2  10--14  years  (2nd  dose
after  one  month)
Switzerland  2  11--15  years  (2nd  dose
after  one  month)
Turkey  1  12  months
Western  Paciﬁc
Australia  2  18  months  and  10--15
years
Korea  1  12--15  months
Americas
Bahamas  2  1  year  4--5  years
Barbados  1  After  18  years  of  age
Brazil 1  15  months
Canada  2  12  months  and  18  months
Costa  Rica 1  15  months
Ecuador  1  12--23  months  or  6--10
years
Panama 1  15--18  months
Paraguay 1  15  months
United  States  2  12--15  months  and  4--6
years
Uruguay  1  1  year
The continents were divided in accordance with the United
Nations (UN) standard.
Source:  World Health Organization [http://apps.who.int/
immunization monitoring/globalsummary/schedules 6] (May/
2015).13
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to  predict  the  impact  of  this  strategy  in  Brazil  for  the  coming
years.
Method
Using  the  vaccine-preventable  diseases  monitoring  system  of
the  World  Health  Organization  (WHO;  http://apps.who.int/
immunization  monitoring/globalsummary/schedules),  the
countries  that  have  already  implemented  universal  VV  were
identiﬁed  and  the  immunization  schedule  adopted  was
veriﬁed.
At  the  same  time,  a  literature  search  was  conducted
at  PubMed,  using  the  keywords  ‘‘varicella’’+‘‘vaccination/
vaccine’’+‘‘children’’  and  ‘‘varicella’’+‘‘vaccination/
vaccine’’+‘‘hospitalization.’’  Articles  published  after  1995
(the  year  of  introduction  of  VV  in  the  USA)  that  presented
the  impact  of  universal  VV  in  varicella-related  hospital-
ization  rates  in  the  previously  identiﬁed  countries  were
selected.  The  search  included  articles  published  in  English;
studies  that  evaluated  countries/regions  where  the  vaccine
was  implemented  only  in  the  private  healthcare  system
were  excluded.
To  observe  possible  similarities  among  the  data  published
by  different  countries,  data  on  the  impact  of  VV  in  children
aged  1--4  years  were  preferentially  sought  after,  as  this  is
usually  the  age  group  with  the  highest  rates  of  varicella-
related  hospitalization.  The  epidemiological  situation  ﬁve
years  after  the  introduction  of  universal  vaccination  in  these
countries  was  assessed.  The  immunization  coverage  and  the
vaccination  schedule  (one  or  two  doses)  adopted  by  these
countries  were  considered.  In  addition,  varicella-related
hospitalization  was  deﬁned  as  cases  in  which  varicella  was
the  main  diagnosis  or  part  of  the  hospitalization  diagnoses.
Results
In  a  search  conducted  in  May  2015  on  the  WHO  website
(which  still  presented  data  on  vaccine  schedules  from  2014),
it  was  observed  that  24  countries  had  adopted  the  VV  univer-
sally  (Table  1):  eight  in  Europe,  ten  in  the  Americas,  four  in
the  Eastern  Mediterranean,  and  two  in  the  East  Paciﬁc.13
Furthermore,  another  12  countries  --  Argentina,  Bahrain,
Slovenia,  France,  Grenada,  Iran,  Iceland,  Kuwait,  Mexico,
United  Kingdom,  Saint  Lucia,  and  Trinidad  and  Tobago  --
indicated  the  vaccine  to  speciﬁc  populations:  healthcare
workers,  children  with  cancer  (and  their  contacts),  and
groups  with  risk  of  severe  disease  progression.  Half  of  the
countries  adopted  the  single-dose  schedule  and  the  other
half,  two-doses.  Most  countries  chose  immunize  infants  aged
12--18  months,  with  a  booster  (when  the  two-dose  schedule
was  chosen)  after  a  few  months  or  at  4--6  years;  Switzer-
land,  Barbados,  and  some  autonomous  regions  of  Spain  have
chosen  to  vaccinate  susceptible  adolescents  only.
In  a  search  conducted  at  PubMed  (May  2015),  2059  results
were  retrieved,  1683  of  which  were  published  after  1995;
of  these,  28  showed  the  impact  of  the  VV  in  varicella-
related  hospitalization  (Fig.  1)  in  seven  countries  that  have
universally  adopted  the  vaccine.  Furthermore,  a  review  by
Helmut  et  al.  with  recent  data  on  incidence,  hospitalization,
and  mortality  related  to  varicella  in  Europe  was  retrieved,
A
s
ta In accordance with the World Health Organization, Israel was
included in the group of European countries.
ncluding  some  countries  that  have  already  implemented
niversal  VV.14
Table  2  shows  the  countries  with  the  greatest  impact  in
educing  vaccine-related  hospitalizations  after  the  inclusion
f  VV  in  the  routine  vaccination  schedule.
SAs  a  pioneer  in  the  introduction  of  VV  in  the  vaccination
chedule  (1995),  the  USA  has  the  largest  number  of  publica-
ions,  12.  The  ﬁrst  three  described  the  impact  of  the  vaccine
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Table  2  Impact  of  varicella  vaccine  in  hospitalization  rates  in  the  analyzed  countries.
Country  Reduction  in  hospitalization
rate  (%)a
Age  range
(year)
Years  of
observationb
Vaccination
coverage  (%)
USA2 >99.2 0--1 15  90
Spain (Navarra)38 95.2  <15  5  >89
Uruguay26 94.0  1--4  6  96
Canada29 93.0  1--4  10  93
Italy (Puglia)33 84.0  1--4  7  91.1
Germany (Bavaria)30 77.6  <5  5  52.7
Australia37 76.8  1--4  5  90
a Comparing the pre-vaccine period with the post-vaccine universaliz
b After vaccine universalization. The highest value observed in the an
and  compared  varicella-related  hospitalization  rates  in  the
pre-vaccine  period  with  those  at  2--4  years  after  the  intro-
duction  of  the  vaccine,  and  found  an  increased  vaccine
coverage:  43.2%  in  1998  and  59%  in  1999.5,15,16 In  ﬁrst  two
years  period  study,  there  was  no  decrease  in  the  varicella-
related  hospitalization  rates,  and  the  results  for  the  ﬁrst
four  years  indicated  a  reduction  of  23.5%.15,16 In  2004,  Davis,
Patel,  and  Gebremarian  published  a  survey  by  the  Nation-
wide  Inpatient  Sample,  with  varicella  related  hospitalization
data  between  1993  and  2001,  and  assessed  the  impact  of
the  VV  over  the  ﬁrst  six  years  after  its  introduction:  the  rate
between  1993  and  1995  was  5/100,000  population,  and  it
was  reduced  to  1.3/100,000  in  2001,  resulting  in  a  decrease
of  74%.  Considering  only  the  age  group  of  0--4  years,  this
28 articles
1683 articles
2059 articles
PubMed 
(search performed on 
May 2015)
Articles on the impact of the
vaccine in one of the 24
countries selected
Publications after 1995 
(year of universal 
varicella vaccination 
onset – USA)
Keywords:
“varicella”+
“vaccination/vaccine”+
“children”+ 
Figure  1  Search  performed  in  PubMed.
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alyzed studies was considered (including regional studies).
eduction  was  even  greater:  81.8%  (29.2  to  5.3/100,000),
ith  vaccine  coverage  of  76.3%  at  the  end  of  the  study
eriod.  The  study  also  indicated  a  decrease  in  the  estimated
ost  of  varicella-related  hospitalizations,  from  US$  161.1
illion  in  1993  to  US$  66.3  million  in  2001  (a  reduction  of
8.8%).17 In  the  following  17  years,  studies  with  observa-
ion  periods  ranging  seven  to  ten  years  after  introduction
f  the  vaccine  have  been  published,  observing  reductions
hat  ranged  from  59.1%  and  92.5%  in  hospitalization  rates,
ccording  to  the  assessed  age,  with  a  vaccine  coverage
hat  reached  90%.18--22 In  2006,  the  USA  introduced  a  sec-
nd  dose  of  VV  for  children  between  4  and  5  years,  and  the
ost  recent  studies  present  data  on  the  impact  of  VV  over
he  15  years  of  its  implementation,  including  three  to  four
ears  from  the  introduction  of  the  second  dose.  There  was
5.6%  reduction  in  varicella-related  hospitalization  rates  in
he  general  population  between  1994  and  2006  (2.13  to
.52/100,000)  and  of  88.3%  between  1994  and  2009  (2.13  to
.25/100,000).  Considering  only  the  impact  of  the  second
ose,  51%  reduction  in  admissions  was  observed  between
006  and  2009.2 When  the  impact  of  the  vaccine  in  chil-
ren  aged  0--4  years  was  assessed,  hospitalization  rates  were
educed  by  90.6%  between  1994  and  2006  and  by  >99.2%
etween  1994  and  2009.  Other  articles  have  described  the
mpact  of  the  second  dose  of  the  vaccine  not  only  in  hospital-
zation  rates,  but  also  in  the  reduction  of  varicella  incidence
nd  outbreaks.23--25
ruguay
ruguay  was  the  second  country  to  include  VV  in  the  immu-
ization  schedule  (1999),  in  a  single-dose  regimen  at  12
onths;  since  the  beginning  of  universal  vaccination,  vac-
ine  coverage  between  88%  and  96%  (depending  on  the
egion)  has  been  reached.  As  a consequence,  the  country
chieved  a  reduction  of  81%  in  the  varicella-related  hospi-
alization  rate  in  the  general  population,  and  94%  decrease
n  children  aged  1--4  years  from  1999  to  2005.26
anadahe  implementation  of  universal  VV  in  Canada  occurred
radually;  the  ﬁrst  ﬁve  provinces  (and  territories)  started
mmunization  between  2000  and  2002,  and  the  remaining
ight,  between  2004  and  2007,  hindering  the  estimation
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of  vaccination  coverage,  which  in  2013  ranged  between
67.0%  and  97.2%.  One  dose  schedule  between  12  and  18
months  (with  a  booster  after  2010)  was  supplemented  in
some  territorial  units  with  a  two-dose  schedule  for  sus-
ceptible  adolescents  (>12  years).  The  ﬁrst  study  of  the
impact  of  the  vaccine  on  varicella-related  hospitalization
rates  observed  a  48%  reduction  in  the  Alberta  province  after
one  year  (2001--2002)  of  VV  universalization.27 A  reduction
of  90.1%  (172  to  17  hospitalizations/100,000  children  aged
1--4  years)  was  described  by  Tan  et  al.,  when  comparing
the  mean  admissions  per  year  in  2000--2002  with  the  2008
result,  including  regions  two  to  eight  years  after  universal
vaccination  onset.28 Another  Canadian  study  reported  a  fur-
ther  reduction  of  70%  on  admission  of  individuals  below  40
years,  and  of  65%--93%  in  children  aged  between  1  and  4
years,  including  regions  three  to  ten  years  after  universal
vaccination  onset.29
Germany
The  country  initially  adopted  a  single  dose  regimen  to  chil-
dren  aged  11--14  months  in  2004;  ﬁve  years  later,  the  second
dose  was  implemented  for  children  aged  15--23  months.
The  results  achieved  were  described  in  two  articles.  One
described  the  impact  of  the  vaccine  speciﬁcally  in  the  state
of  Bavaria.  In  that  state,  ﬁve  years  after  the  implemen-
tation  of  universal  vaccination  (53%  coverage),  there  was
a  77.6%  decrease  (from  21  to  4.7/100,000)  in  varicella-
related  hospitalizations  in  children  under  5  years  of  age.
Another  study,  conducted  at  the  national  level  by  Siedler
and  Dettmann  between  1995  and  2012,  indicated  a  reduc-
tion  in  varicella-related  hospitalization  rates  of  62.4%  (from
21.8  to  8.2/100,000)  in  children  between  1  and  4  years,  with
a  vaccine  coverage  of  78.2%  for  one  dose  and  67.6%  for  two
doses.30,31
Italy
According  to  the  WHO,  Italy  is  among  the  countries  that
already  offer  VV  universally;  however,  four  studies  retrieved
on  the  impact  of  the  vaccine  in  Italy  indicated  that,  of  the
21  Italian  regions,  only  eight  (Puglia,  Basilicata,  Calabria,
Friuli-Venezia  Giulia,  Sardinia,  Sicily,  Tuscany,  and  Veneto)
adopted  the  vaccine  (ﬁrst  dose  between  13  and  15  months
of  age  and  second  dose  between  5  and  6  years).  The  vac-
cine  was  implemented  between  2003  and  2013,  depending
on  the  region,  and  resulted  in  a  mean  decrease  of  70%--75%
in  the  hospitalization  rate  in  the  general  population,  with  a
vaccination  coverage  ranging  between  60%  and  95%.32 Other
publications  presented  local  data:  the  varicella-related  hos-
pitalization  rates  in  the  Veneto  region  decreased  73.6%
(from  44.3  to  11.7/100,000  children  aged  1--4  years)  three
years  after  the  onset  of  universal  vaccination  against  the
disease,  with  a  vaccination  coverage  of  78.6%;  in  Puglia,
an  84%  reduction  (from  35.1  to  5.6/100,000  children  aged
1--4  years)  in  varicella-related  hospitalization  rates  was
observed  after  seven  years,  with  a  vaccination  coverage
above  90%;  ﬁnally,  in  Sicily,  a  reduction  of  83.3%  (from
4.8  to  0.8/100,000)  in  varicella-related  hospitalizations  was
observed  ten  years  after  universal  vaccination  onset,  with  a
vaccine  coverage  of  84.7%.1,33,34
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ustralia
V  was  universally  introduced  in  Australia’s  public  health-
are  service  in  2005,  with  the  ﬁrst  dose  at  18  months  and
he  second  between  10  and  15  years.  Three  articles  have
escribed  the  impact  of  this  vaccine  in  varicella-related  hos-
italization  rates.  The  ﬁrst,  from  2010,  refers  to  the  data  of
he  State  of  Victoria,  which  presented  a  rate  of  38.6/100,000
hildren  under  4  years  between  1995  and  1999  (the  period
rior  to  the  vaccine  licensing  in  the  country)  and  observed
 reduction  to  19.4/100,000  (<4  years)  between  2006  and
007  -- a  decrease  of  49.7%,  with  a  78%  vaccine  coverage.35
fter  three  years,  Marshall  et  al.  assessed  the  rate  of
aricella-related  hospitalizations  in  four  tertiary  hospitals
n  Australia  and  found  a  reduction  of  73.2%  when  compar-
ng  a  period  prior  to  VV  (1999--2001)  with  a  later  sampling
2007--2010).36 Finally,  in  2014,  Heywood  published  a  nation-
ide  study  in  which  the  pre-vaccine  period  (1998--2000)  was
ompared  with  the  post-vaccine  (2006--2010),  observing  a
ecrease  of  57.3%  in  varicella-related  hospitalization  in  the
eneral  population,  more  pronounced  (76.8%,  from  83.3  to
9.3/100,000)  in  children  aged  1--4  years,  with  a  vaccine
overage  of  82%--90%.37
pain
n  Spain,  universal  VV  has  been  implemented  from  2006
nwards,  with  different  strategies  by  region,  as  these  are
eﬁned  by  the  regional  governments.  Some  regions  have
hosen  to  vaccinate  infants  at  15  months,  with  a  booster
t  age  3  years,  and  others  have  decided  to  immunize  sus-
eptible  adolescents  with  one  or  two  doses  of  the  vaccine.
avarra  adopted  the  ﬁrst  option  in  2007;  after  ﬁve  years,
 95.2%  reduction  in  varicella-related  hospitalization  rates
from  20.9  to  1.0/100,000)  was  observed  in  children  under
5  years,  with  vaccine  coverage  greater  than  89%  for  two
oses.38 In  2014,  Gil-Prieto  presented  national  statistics  on
he  impact  of  VV  and  revealed  a  decrease  of  83.5%  (from
2.7  to  7.04/100,000)  in  children  under  5  years  in  the
egions  where  infants  were  vaccinated,  and  a  35.8%  reduc-
ion  (from  46.4  to  29.8/100,000)  for  the  same  age  group
n  areas  where  susceptible  adolescents  were  vaccinated.
he  same  author  described  signiﬁcant  regional  differences
n  varicella-related  hospitalization  rates,  with  data  ranging
rom  12.08  to  51.55  hospitalizations  per  100,000  children
nder  5  years,  with  clear  advantage  for  the  regions  with
reater  coverage  vaccine.39,40
Table  2  shows  the  countries  with  the  greatest  reductions
f  varicella-related  hospitalizations  after  the  vaccine  was
ncluded  in  the  routine  schedule.
razil
n  Brazil,  the  ﬁrst  publication  including  data  on  the  impact
f  the  VV  was  a  study  comparing  the  incidence  of  varicella  in
hildren  from  Florianópolis  --  a  city  that  implemented  VV  in
he  population  under  2  years  old  in  2002  --  and  the  remainder
f  the  state  of  Santa  Catarina.41 The  study  observed  a  75.5%
ecrease  in  the  incidence  rate  of  the  capital,  compared  with
he  rest  of  state,  in  children  aged  1--4  years,  and  compared
he  pre-  and  post-vaccination  period,  but  the  study  failed  to
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resent  data  on  hospitalization  rates.  At  the  2015  meeting
f  the  European  Society  of  Paediatric  Infectious  Diseases,
ndrade  et  al.  presented  a  case--control  study  on  the  effec-
iveness  of  the  vaccine  introduced  in  Brazil  in  2013  in  two
razilian  cities,  Goiânia  and  São  Paulo,  with  vaccination  cov-
rage  of  74%  and  78%,  respectively.42 These  authors  showed
hat,  during  the  ﬁrst  year  of  VV  implementation,  the  group
f  children  with  varicella  had  a  smaller  proportion  (18.8%)
f  vaccinees  when  compared  with  the  control  group  (54%).
he  effectiveness  of  the  vaccine  was  86.5%  (95%  conﬁdence
nterval:  70.2%--94.1%)  for  moderate  and  severe  forms  of  the
isease.
iscussion
lthough  the  ﬁrst  three  American  publications  on  the  impact
f  universal  VV  did  not  demonstrate  a  statistically  signiﬁ-
ant  reduction  in  varicella-related  hospitalization  rates,  or
bserved  only  a  modest  reduction,  this  can  be  explained
y  the  short  observation  period  after  vaccine  implementa-
ion  (2--4  years)  and  low  vaccination  coverage  (<60%)  in  the
arly  years  of  VV  introduction.  All  subsequent  publications
valuated  in  this  review,  both  from  the  USA  and  the  other
ountries,  demonstrated  that  VV  universalization  resulted
n  signiﬁcant  reductions  in  hospitalization  rates.  The  results
re  highly  variable;  the  smallest  decrease  in  the  described
ospitalization  rate  was  30.9%  for  the  general  population  of
he  State  of  Victoria  (Australia)  and  the  highest,  99.2%,  in
hildren  aged  0--4  years  in  the  USA.2,35 This  large  discrep-
ncy  in  values  is  understandable  when  considering  that  ﬁrst
esult  reported  only  two  years  period  after  universal  vaccine
nset,  included  the  hospitalization  rate  of  the  entire  popu-
ation,  with  a  one-dose  vaccination  schedule  for  infants,  and
accination  coverage  of  78%,  while  the  second  assessed  the
ituation  after  14  years  of  vaccine  introduction,  considered
he  speciﬁc  age  group  of  children  up  to  4  years,  with  a  two-
ose  vaccination  schedule  and  vaccination  coverage  of  90%.
Greater  decrease  in  varicella-related  hospitalization
ates  is  expected  when  considering  a  longer  period  of
ime  after  the  adoption  of  universal  vaccination,  when  the
tatistic  refers  to  infants  and  preschoolers  (the  age  group
enerally  most  affected  by  the  disease),  and  when  vaccine
overage  is  higher.  Thus,  although  Table  2  lists  the  results
f  hospitalization  reduction  in  countries  that  have  adopted
he  vaccine,  a  direct  comparison  of  the  data  is  unworkable.
here  are  important  differences  in  studied  age  groups  (0--4
ears,  1--4  years,  <15  years),  in  time  period  analyzed  after
V  introduction  (1--15  years),  in  vaccination  schedule  (some
ountries  with  one  dose,  others  with  two),  and  in  strategies
egarding  vaccination  age.  Furthermore,  a  highly  variable
accine  coverage  was  observed  among  the  studies:  from
2.9%  to  96%.  While  US  publications  show  the  importance
f  the  second  dose  of  the  vaccine,  it  is  difﬁcult  to  say  that
ountries  that  have  adopted  two  doses  had  better  results
han  those  who  adopted  a  single  dose  with  high  vaccination
overage,  as  shown  in  the  Uruguayan  experience,  which  pro-
ided  excellent  results  from  the  use  of  a  single  dose  with
igh  vaccination  coverage.2,23,26
Another  issue  that  could  explain  the  difference  in  results
s  the  wide  variation  in  varicella-related  rates  of  hospitaliza-
ions  in  the  pre-vaccine  period  (USA:  29/100,000;  Australia:
C
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4/100,000;  Spain:  21/100,000;  and  Italy:  44/100,000),
hich  created  different  pre-vaccine  baselines  among  the
arious  locations.  Those  with  the  highest  rates  before  VV
mplementation  tend  to  demonstrate  a  greater  impact  from
accine.  One  of  publications  indicated  speciﬁc  populations
f  native  Americans  and  Alaskans,  who  presented  varicella-
elated  hospitalization  rates  three  times  higher  than  the
merican  average  in  pre-vaccine  period,  had  one  of  the
argest  reductions  in  this  statistic  (greater  than  95%)  in
he  post-vaccine  period.25 Likewise,  some  countries  had
ad  a  reasonable  vaccination  coverage  against  varicella  in
rivate  healthcare  system  when  universal  vaccination  was
ntroduced.  Some  Canadian  age  group  reached  28%  in  that
ind  of  coverage,  while  in  Veneto  this  rate  was  estimated  at
.8%.  The  impact  of  the  vaccine  tends  to  be  higher  in  areas
ith  lower  vaccination  coverage  (by  the  private  healthcare
ystem)  in  the  period  prior  to  vaccine  universalization.1,43
he  admission  criteria  and  the  admissions  notiﬁcation  sys-
ems  also  differ  from  one  country  to  another,  hindering
omparative  analysis.
Several  studies  indicate  that,  after  VV  universaliza-
ion,  reductions  in  varicella-related  hospitalizations  were
bserved  in  non-vaccinated  age  groups,  such  as  children
nder  1 year  and  teenagers,  demonstrating  the  indirect  ben-
ﬁt  of  universal  varicella  vaccination  on  the  population  as  a
hole,  an  effect  known  as  herd  immunity.1,25,28,29,39
onclusions
n  addition  to  outlining  countries  that  have  already  imple-
ented  VV  this  review  showed  that,  20  years  after  the
ntroduction  of  VV  in  American  vaccination  calendar  (1995),
here  has  been  a  growing  interest  by  scientiﬁc  community
n  monitoring  the  impact  of  this  measure  on  the  reduc-
ion  of  incidence,  hospitalization,  and  mortality  related  to
he  disease,  which  is  reﬂected  by  signiﬁcant  increase  of
ublications  on  the  subject  from  1995  onwards.  Observed
eductions  in  hospitalization  rates  between  62.4%  and  99.2%
annot  be  directly  compared  due  to  lack  of  uniformity  in  the
ge  group  studied,  time  from  vaccination  onset,  vaccination
chedule  vaccination  coverage,  and  hospitalization  criteria,
mong  other  factors.
After  inclusion  of  VV  in  the  National  Immunization  Pro-
ram  in  Brazil  in  2013,  the  annual  rates  of  varicella-related
ospitalization  are  expected  to  reduce.  Although  these
esults  may  be  scarcely  evident  in  the  early  years,  as
ccurred  in  the  USA,  the  high  vaccination  coverage  observed
n  Brazil  may  promote  a  faster,  sharper  reduction  in  this
tatistic.  It  is  critical  to  study  the  pre-vaccination  data  in
razil  in  order  to  measure  real  impact  of  introduction  of
V  in  coming  years,  as  well  as  to  assess  the  need  for  the
mplementation  of  second  dose  vaccine  in  the  future.
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